製品名:3-Indolylacetone

IUPAC Name:1-(1H-indol-3-yl)propan-2-one

CAS番号:1201-26-9
分子式:C11H11NO
純度:95%+
カタログ番号:CM148642
分子量:173.22

包装単位 有効在庫 価格(USD) 数量
CM148642-25g in stock ŹƓʼn

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:1201-26-9
分子式:C11H11NO
融点:-
SMILESコード:CC(CC1=CNC2=C1C=CC=C2)=O
密度:
カタログ番号:CM148642
分子量:173.22
沸点:341.7°C at 760 mmHg
MDL番号:MFCD00047187
保管方法:Store at 2-8°C.

Category Infos

Indoles
Indole is a compound of pyrrole and benzene in parallel, also known as benzopyrrole. There are two combinations of pyrrole and benzene, called indole and isoindole, respectively. Many derivatives of indole have physiological and pharmacological activities, and can synthesize vasodilators, antihistamines, antipyretic analgesics, etc. in medicine, so indole is also a very important heterocyclic compound.
indole company
As a indole company,we sincerely welcome the new and old friends from home and abroad to synergize with our company and share the benefits and opportunities.

Column Infos

Palazestrant
Olema Oncology is advancing the development of Palazestrant (OP-1250) in metastatic breast cancer in 2024. Palazestrant is an oral complete ER antagonist (CERAN) and selective ER degrader (SERD). It potently binds and completely blocks transcriptional activity of both wild-type and ESR1-mutant ER with favorable tolerability and anti-tumor activity.
Palazestrant is under clinical development both in combination with Novartis' CDK4/6 inhibitor Kisqali (Ribociclib) as a first-line therapy for advanced estrogen receptor-positive, HER2-negative breast cancer, and as a monotherapy compared to standard of care treatment in second- and third-line advanced or metastatic ER-positive, HER2-negative breast cancer.